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Abstract
Iron metabolism has been intensively examined over the last decade and there are many new players in this field which are worth to be introduced. 
Since its discovery many studies confirmed role of liver hormone hepcidin as key regulator of iron metabolism and pointed out liver as the central 
organ of system iron homeostasis. Liver cells receive multiple signals related to iron balance and respond by transcriptional regulation of hepcidin 
expression. This liver hormone is negative regulator of iron metabolism that represses iron efflux from macrophages, hepatocytes and enterocytes 
by its binding to iron export protein ferroportin. Ferroportin degradation leads to cellular iron retention and decreased iron availability. At level of a 
cell IRE/IRP (iron responsive elements/iron responsive proteins) system allows tight regulation of iron assimilation that prevents an excess of free in-
tracellular iron which could lead to oxidative stress and damage of DNA, proteins and lipid membranes by ROS (reactive oxygen species). At the same 
time IRE/IRP system provides sufficient iron in order to meet the metabolic needs. 
Recently a significant progress in understanding of iron metabolism has been made and new molecular participants have been characterized. Article 
gives an overview of the current understanding of iron metabolism: absorption, distribution, cellular uptake, release, and storage. We also discuss 
mechanisms underlying systemic and cellular iron regulation with emphasis on central regulatory hormone hepcidin. 
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Iron is essential element involved in a broad range 
of biologically important reactions critical for cel-
lular function and also plays fundamental role in 
oxygen transferring . Disorders of iron homeosta-
sis are among the most common human disor-
ders (1) . Although it is the fourth most abundant 
element in Earth´s crust, iron bioavailability is very 
low and despite a low daily requirements iron de-
ficiency is the most common nutritional disorder 
in the world (2,3) . On the opposite end of the iron 
disorders spectrum there are iron overload dis-
eases which represent heterogeneous group of 
hereditary as well as acquired conditions . Heredi-
tary hemochromatosis (HH) is a common inherit-
ed metabolic disease in people of Northern Eu-
rope (4) . Excessive iron accumulation leads to the 
damage of liver, heart, pancreas and other organs . 
Beside systemic disorders of iron homeostasis lo-
cal mismanagement of iron plays a role in several 
disorders . Neuronal disturbance of iron homeo-
stasis and deposition of excessive iron in brain is 
associated with neurodegenerative disorders 
such as Parkinson´s disease, Alzheimer´s disease 
and Friedriech´s ataxia (5,6) . Accumulation of mi-
tochondrial iron is characteristic of sideroblastic 
anemia, erythropoietic protoporphyria and mye-
lodisplastic syndrome (7) . Furthermore, disturbed 
iron physiology mediated by proinflammatory cy-
tokines and hepcidin leads to anemia of chronic 
disease (ACD) associated with various types of in-
fections, hematologic malignancies, solid cancers, 
autoimmune disorders (8) . Recently, a significant 
progress in understanding of iron metabolism 
has been made and new molecular participants 
have been characterized . Article gives an over-
view of the current understanding of iron metab-
olism: absorption, distribution, cellular uptake, re-
lease, and storage . We also discuss mechanisms 
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bearing ages almost lack iron reserve . A small 
amount of residual iron in the body is in the form 
of myoglobin in the muscles or incorporated in 
enzymes (11) . Amount of iron bound to transferrin 
is about 3 mg, but this iron transport compart-
ment is very dynamic and changes about 10 times 
during the day (Figure 1) .
Body iron stores 
Body iron is stored in the liver, in both hepato-
cytes and Kupffer cells, in form of ferritin and he-
mosiderin . When cellular iron exceeds require-
ments the excessive iron is stored in bioavailable 
form as ferrritin which protects cells from poten-
tially toxic reactions catalyzed by iron (15) . Ferritin 
thus has got dual function of iron detoxification 
and reserve . It is composed of 24 subunits of two 
types: H (heavy or hart Mr ~ 21 kDa) and L (light 
or liver Mr ~ 19 kDa) forming a spherical struc-
ture . The ratio of H and L subunits within the as-
sembled ferritin protein varies depending on tis-
sue type . Incorporation of iron into ferritin re-
quires ferroxidaze activity that is attributed to H 
subunit while L subunit has a role in mineraliza-
tion (16) . Mature ferritin has got a molecular 
weight of about 450 kDa and is capable to accu-
mulate up to 4,500 iron atoms (12) . Ferritin stored 
iron will be utilized when cell become iron defi-
cient but mechanism underlying the ferritin iron 
release have yet to be completely elucidate 
(13,17,18) .
Although the most of mature ferritin is located in 
the cytoplasm of cells, a small fraction was also 
found in nucleus of some cells . In the nucleus, fer-
ritin could serve for delivering iron to iron-de-
pendent enzymes or transcription factor activities 
but could also have a role of free iron “scavenger” 
that might otherwise catalyze DNA oxidative dam-
age (19,20) .
Also, human mitochondrial ferritin (MtF) is re-
cently discovered . Mitochondria are organelles 
that exhibit a very high iron turnover carrying 
out the biosynthesis of heme and enzymes that 
contain Fe-S group . Since both mitochondrial 
iron deficiency and excess impair the metabolic 
underlying systemic and cellular iron regulation 
with emphasis on central regulatory hormone 
hepcidin . 
Iron as double distress in living 
organisms
Iron is involved in a broad range of biologically 
important reactions . It is a component of innu-
merable hemoproteins including oxygen trans-
port proteins, heme containing enzymes and 
many essential non-heme iron proteins that cata-
lyse a wide range of reactions and have a central 
role in mechanism for oxygen sensing (Table 1) (9-
11) . Iron is a transition metal and it exists in two 
readily reversible redox states: reduced ferrous 
(Fe(II)) form and oxidized ferric (Fe(III)) form . At 
physiological oxygen concentrations the stable 
state of iron in most of its biological complexes is 
Fe(III) (12) . Reduction reactions play a crucial role 
in the iron metabolism, because only reduced 
iron ion can be a substrate for transmembrane 
transport of iron, loading and releasing of iron 
from ferritin and for heme synthesis (12,13) . Al-
though biological function of iron is largely attrib-
utable to its chemical properties as a transition 
metal, exactly these properties render it poten-
tially toxic . Iron excess is believed to generate oxi-
dative stress due to its ability to generate ROS 
(7,14) . Fe(II) catalysed reduction of one electron in 
O2 molecule results in the formation of superox-
ide anion which further leads to the sequence of 
well-known Haber-Weis-Fenton´s reactions that 
generate ROS which can possibly damage macro-
molecules such as proteins, lipids and nucleic ac-
ids (12) .
Distribution of iron in the body
Body iron content of an adult is 3-5 g (~ 45 mg / 
kg woman, ~ 55 mg / kg for men) . Most of the 
body iron is incorporated in hemoglobin of circu-
lating erythrocytes (60-70%) . Approximately 20-
30% is in the form of ferritin and hemosiderin in 
hepatocytes and RES macrophages as a spare 
iron . While adult male has a 0 .5-0 .2 g of stored 
iron, children, adolescents and women of child-
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and respiratory activities of the mitochondria, 
iron homeostasis within organelle must be strict-
ly controlled . It is assumed that ferritin could play 
a role in storing iron within mitochondria pro-
tecting it from oxidative stress (21) . MtF is ex-
pressed at extremely low levels in most cells . 
Studies have shown that MtF overexpression sig-
nificantly affects intracellular iron homeostasis 
leading to a rapid redistribution of iron from cy-
tosol to mitochondria where it is deposited in a 
form unavailable for metabolic use (22,23) . Re-
cent study indicates that up-regulation of MtF in 
erythroid progenitors may interfere with either 
the JAK2/STAT5 regulatory pathway or heme 
Iron containing proteins
oxygen transport heme containing proteins (hemoglobin, myoglobin, neuroglobin)
heme containing enzymes (cytochromes, catalase, peroxidase)
iron-sulfur containing enzymes (aconitase, ferrochelatase)
proteins that play role in iron transport (transferrin)
proteins that play role in iron storage (ferritin – cytoplasmic and mitochondrial form; hemosiderin)
Proteins involved in iron transport 
DMT 1 (Nramp2, DCT1) mediates transport of divalent metal cations on apical membrane of the duodenal enterocytes and 
membranes of endosomes (40,41)
Ferroportin (IREG1, MTP-1) export of ferrous iron (54,55)
HCP1 heme moiety absorbtion in intestinal enterocytes (10,47)
Integrin-mobilferrin transports ferric iron on apical membrane of the duodenal enterocytes (42,43)
TfR1 membrane receptor for Fe2-Tf, binds transferrin and mediates transferrin cycle (71)
Proteins assisting in iron transport
DcytB enzymatic reduction of dietary ferric iron on brush border of duodenal enterocytes (37,64)
Ceruloplasmin ferroxidase; change redox state of iron promoting its release from cells (57,149)
Hephaestin membrane bound ferroxidase, change redox state of iron during basolateral export from the enterocyte (56)
Heme oxygenase-1 catalyses the release of iron from protoporphyrin ring during heme degradation (78)
Iron binding proteins
Lactoferrin free iron scavenger in different body fluids (150)
Siderocalin (NGAL, lipocalin 2) sequestration of iron, acute phase protein (151)
Molecules involved in regulation of iron homeostasis
Erythropoietin (EPO) hormone essential for erythroid differentiation; erythroid regulator of hepcidin expression (123)
Frataxin mitochondrial protein involved in cellular iron homeostasis (152)
Growth differentiation factor 15 (GDF15) secreted by hemoglobinized erythroblasts during the final stages of erythropoiesis; 
erythroid regulator of hepcidin expression (124)
Hepcidin (LEAP-1) liver hormon, negative regulator of iron metabolism (91,92)
Hemojuvelin (RGMc, HFE2) - molecule involved in hepcidin regulation by iron status (101,104,106)
HFE hereditary hemochromatosis protein mutated in type I HH (69)
IRP1/ IRP2 ˝sense˝ level of iron in transit pool and posttranscriptionally modify the expression of proteins involved in iron 
metabolism (131-133)
TfR2 transferrin receptor type 2 involved in hepcidin regulation by iron status (67,100,103)
Matriptase-2 (TMPRSS6) essential component of a pathway that detects iron deficiency (107,108)
Twisted gastrulation (TWSG1) serine protease produced mainly by the immature erythroid precursors, the newest erythroid 
regulator of hepcidin expression (125)
Table 1. Key proteins involved in iron homeostasis .
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synthesis, contributing to ineffective erythro-
poiesis (24) .
Although most ferritin is used to store iron within 
cells, very small amount enters into circulation . 
The source and detailed secretory pathway of fer-
ritin are not completely understood but its bio-
physical characteristics imply active secretion 
through the lysosomal secretory pathway (25,26) . 
Plasma ferritin is almost non-ferous, and its exact 
biologic purpose is still unknown . Some authors 
hypothesize that it may have a role as iron scav-
enger and modulator of inflammation (27) . Stud-
ies have shown that extracellular ferritin can func-
tion as an iron carrier to provide iron to cells 
(28,29) . Ferritin receptors are presented on lym-
phocytes and on some other cell types, but their 
physiological functions have not been fully de-
fined (30) . The plasma ferritin concentration is 
used as useful indicator of iron stores (31) . It has 
been estimated that plasma ferritin concentration 
of 1 µg/L corresponds to 8-10 mg tissue iron 
stores (32) . 
Another form of stored iron in the cell is hemosid-
erin, insoluble degradation product of incomplete 
lysosomal degradation of ferritin . In iron overload-
ing conditions hemosiderin becomes the predom-
inant iron storage protein . Under physiological 
conditions hemosiderin is not an effective iron do-
nor but plays a protective role . Subject to condi-
tions such as inflammation and hypoxia it could 
become an iron donor promoting free radical pro-
duction and tissue damage in iron overloaded 
cells (33) .
Intestinal iron absorption
There is no known regulated pathway of iron ex-
cretion so body iron content is regulated by pre-
cisely controlled intestinal absorption . The intesti-
nal mucosa responds to changes in body iron 
Figure 1. Body iron distribution . 
Most of the body iron is incorporated in hemoglobin of circulating erythrocytes (60-70%) . Approximately 20-30% of iron in the body 
is in the form of ferritin and hemosiderin in hepatocytes and RES macrophages as a spare iron . The amount of iron bounded to trans-
ferrin is about 3 mg but plasma transferrin compartment functions as transit compartment through which flows about 20 mg of iron 
each day . Under circumstances of iron overload NTBI can appear in plasma . The bone marrow is the main consumer of circulating 
iron . 18-20 mg of iron, mostly recycled, is used for hemoglobin synthesis in 200 billion new erythrocytes every day . Healthy people 
absorb 1-2 mg of iron per day which compensates for iron loss .
NTBI - non-transferin bound iron; RBCs - red blood cells; Tf - transferrin .
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stores, tissue hypoxia, and demand for iron, and it 
alters absorption accordingly . Absorption is in-
creased in iron deficiency while is reduced in the 
iron overload . Losses of iron from the body occur 
from desquamated epithelium of the skin, intesti-
nal cells and intestinal secretions . An adult man 
loses only 1 mg of iron per day whereas women 
during reproductive ages lose twice that amount 
due to menstruation bleeding, pregnancy and 
childbirth . Healthy people absorb 1-2 mg of iron 
per day which compensates for iron loss . Iron re-
quirements increase during adolescence due to 
growth and during pregnancy due to expansion 
of the blood volume and growth of the fetus (34) . 
For optimal nutrition a daily intake of 8-10 mg of 
iron is required . 
Dietary iron is present in food as one of two forms 
- as inorganic or heme iron . Inorganic form is dom-
inant in the standard diet, and makes up about 
90% of the total amount present in food . Heme ac-
counts for only 10% of the dietary iron (35) . De-
spite the relatively low participation in diet, heme 
is a highly bioavailable source of iron whose ab-
sorption is significantly more efficient than the ab-
sorption of inorganic form because it is not affect-
ed by the dietary constituents that adversely af-
fect the absorption of inorganic form (36) . 
Absorption of iron is a very complex process that 
takes place in the duodenum and upper jejunum . 
This process involves number of proteins that 
transport iron across the apical membrane (im-
porters), proteins that transport iron through the 
basolateral membrane of enterocyte (exporters), 
proteins that change redox state of iron and thus 
assist in its transport (Table 1; Figure 2A; Figure 
2B) .
Absorption of inorganic iron
The most dietary inorganic iron is in ferric form 
and it must be first reduced by brush border fer-
rireductase, duodenal cytocrome B (DcytB) (37) . 
Some physiological approaches elucidate intra-
cellular duodenal ascorbate as electron donor for 
this reductase . Recently, there are some data 
showing that members of six-transmembrane 
epithelial antigen of the prostate (STEAP) family 
are also expressed in intestine (38) . The exact role 
of both types reductases especially in human 
iron absorption remains uncertain (39) . Ferrous 
Figure 2a. Absorption of iron in the gut .
Dietary iron could be absorbed as ferric, ferrous and heme iron . 
Ferric form must be first reduced to ferrous iron by DcytB . Fe(II) 
is then transported across the apical membrane into the cyto-
plasm of the duodenal enterocytes by DMT-1 . Cellular uptake 
of ferric iron proceeds through a separate pathway, using IMT 
pathway while heme moiety is absorbed by intestinal entero-
cytes via HCP1 . Within the cell iron is released from protopor-
phyrin ring by HO-1 . After apical transport two forms of iron 
enter the inorganic iron pool of the enterocytes and could be 
sequestrated as ferritin or transported across the basolateral 
membrane . Iron basolateral export is carried out by ferropor-
tin and also requires change of its redox state by ferroxydase 
– hephaestin . Ferric iron is captured by transferrin and distrib-
uted throughout the body . 
Figure 2b. Recycling of iron by RES .
RES macrophages in the spleen and elsewhere phagocytize 
and lyse aged or damaged red blood cells . Heme is degraded 
by HO-1 and iron is liberated from protoporphyrin ring . Iron ex-
port by ferroportin requires also change of redox state and is 
accomplished by ceruloplasmin .
Crlp - ceruloplasmin; DMT-1 - divalent metal transporter 1; 
DcytB - duodenal cytocrome b; Fer - ferritin; Fpn - feroporrtin; 
HO-1 - heme oxygenase 1; HCP1 - heme-carrier protein; LIP - 
labile iron pool; NTBI - non-transferin bound iron; RBCs - red 
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iron is then transported across the membrane 
into the cytoplasm via divalent metal transporter 
1 (DMT1) expressed on apical membrane of the 
duodenal enterocytes (40) . DMT1 is not specific 
for iron transport but also mediates transport of 
other divalent metal cations including zinc, man-
ganese and copper although it seems that it’s 
primary physiological role is iron transport 
(12,40) . This transport protein is also expressed 
on the membrane of endosomes where mediates 
iron transport from endosomes into the cyto-
plasm during transferrin cycle (9) . DMT-1 seems 
to have a role in transport of non transferrin 
bounded iron (NTBI), especially in conditions of 
iron excess (41) . 
Some researches have shown that duodenal ferric 
iron uptake proceeds through a separate, al-
though less understood pathway . While ferrous 
iron uses DMT-1, ferric uses integrin-mobilferrin 
pathway (IMT) that solely transports ferric iron, not 
other metals of nutritional importance (36,42) . This 
pathway involves several proteins like mobilferrin, 
beta-3-integrin and flavin-monooxygenase . Fla-
vin-monooxygenase has a role of ferrireductase . In 
the cell cytosol these proteins are integrated into a 
large protein complex called paraferritin (43) . 
Western Blott analysis of paraferritin revealed that 
it also contains beta-2-microglobulin and DMT-1 . 
The presence of considerable fraction of DMT-1, 
mobilferrin and hephaestin in the cytoplasm of 
cells indicates a possible intracellular role of these 
proteins (Figure 2A) (44,45) .
Absorption of heme iron
Transport of heme across the membrane is not re-
quired only for heme iron absorption in gut but 
also for cellular heme turnover . Synthesis of heme 
partially takes place in the mitochondria and after 
that heme must be transported to the endoplas-
mic reticulum to be included in hemoproteines . 
Heme is involved in transcriptional regulation of 
some genes therefore also needs to be transport-
ed in the cell nucleus (46) . Studies have shown that 
intact heme moiety is absorbed by intestinal en-
terocytes via heme-carrier protein 1 (HCP1), trans-
port protein expressed at high levels in duodenum 
(47,48) . Some recent investigation indicated that 
descripted heme intestinal transporter might be 
folate transporter (49) . Within the cell iron is re-
leased from protoporphyrin ring by heme oxyge-
nase 1 (HO-1) and converges with the cytosolic 
iron pool of enterocyte . Afterwards, two forms of 
iron share the same pathway - enter the inorganic 
iron pool of the enterocytes (Figure 2A) . It seems 
that step catalysed by HO-1 is limiting factor in the 
absorption of heme .
Intracellular iron transport
Once iron enters the intestinal epithelial cells 
through the apical membrane, it could be seques-
trated as ferritin or transported into circulation 
across the basolateral membrane . Absorptive en-
terocytes perform their function for two days and 
then are being shed into intestinal lumen . Iron 
that is not exported from enterocytes into the 
plasma is lost by exfoliation of intestinal epitheli-
um . Therefore, transport of iron by ferroportin 
across the basolateral membrane determines 
whether iron is delivered into the circulation or re-
moved from the body with shed enterocytes . Ex-
foliation of epithelial cells of intestinal mucosa 
may represent pathway of regulated iron excre-
tion because these cells at the basolateral mem-
brane express transferrin receptors type 1 (TfR1) 
and iron from the plasma can enter the cell by re-
ceptor mediated endocytosis, but the capacity of 
this mechanism of excretion in response to the ac-
cumulation of iron is very limited (50) . To be trans-
ported through the basolateral membrane iron 
must first be transported through the cell cyto-
plasm . Transport of iron across the enterocyte cy-
toplasm is the least understood step in iron ab-
sorption . There are two possible mechanisms of 
transport that do not exclude each other: trans-
port of iron associated with some proteins (chap-
erones) or transcytosis (51) . Although the molecu-
lar details have yet to be explored, cytosolic mon-
othiol glutaredoxins and Poly(rC)-binding proteins 
could act as iron chaperones and thus may repre-
sent the basic cellular machanism for intracellular 
iron delivery (52,53) .
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Basolateral iron transport
Ferroportin represents the only known iron ex-
porter (54) . This export protein is present in all tis-
sues that export iron into plasma: basolateral 
membranes of duodenal enterocytes, membranes 
of RES macrophages, hepatocytes and placental 
cells . Mutations in ferroportin gene affect iron ex-
port from macrophages and cause type IV hemo-
chromatosys (55) . Iron basolateral export from the 
enterocyte requires also change of redox state by 
ferroxydase - hephaestin in the duodenum and ce-
ruloplasmin elsewhere in the body, that converts 
intracellular Fe(II) back to extracellular Fe(III) (Fig-
ure 2A) (56,57) . Ferroportin expression is increased 
in tissue macrophages as well as in enterocytes in 
response to iron-restricted erythropoiesis (58) . Re-
cent study provided evidence that erythroblasts 
express an important amount of ferroportin at 
their membrane . Authors propose hypothesis that 
in conditions of severe iron deficiency, the high 
ferroportin expression associated with low hepci-
din levels could favour iron export from erythro-
blasts in order to abandon this essential element 
to cells more sensitive to iron deprivation (59) . 
Iron transport in plasma
The plasma transferrin compartment functions as 
transit compartment through which flows about 
20 mg of iron each day (60) . Principles of iron trans-
port are partially dictated by its chemical proper-
ties . Binding of iron to transferrin, a major iron 
transporter in the blood, provide solubility, reduce 
reactivity and thus provides a safe and controlled 
delivery of iron to all cells in the body . Transferrin 
is serum glycoprotein with molecular weight 
about 75–80 kDa . Molecule is folded into two 
globular domains, each containing a specific bind-
ing site for single Fe(III) . Affinity of transferrin mol-
ecule for iron at physiological pH is extremely high 
so almost all non-heme iron in circulation is 
bounded to transferrin (61) . Under circumstances 
of iron overload NTBI appears in plasma . NTBI re-
fers to all forms of iron in the plasma that binds to 
ligands other than transferrin . Iron is bounded to 
these ligands with substantially less affinity than 
to transferrin . This form of iron is very reactive and 
could enter Fenton reaction . NTBI is likely to be a 
major contributor to iron loading in hepatocytes 
under conditions of elevated transferrin satura-
tion, capable to freely enter the cell so it is consid-
ered to be a marker of iron toxicity (62,63) .
Iron uptake in the tissues
Transferrin is taken up into the cell by transferrin 
mediated endocytosis in so called transferrin cy-
cle . Under physiological conditions this cycle ena-
bles controlled access of iron to cells because indi-
vidual cells can efficiently regulate the entry of 
iron by regulating the expression of TfR1 at the 
surface, according to their iron needs . 
Transferrin receptors
Two types of functionally different transferrin re-
ceptors are described, TfR1 and transferrin recep-
tor 2 (TfR2) . TfR1 is expressed by all iron-requiring 
cells but level of expression varies greatly (64) . It is 
highly expressed on immature erythroid cells, rap-
idly dividing cells (normal and malignant), placen-
tal tissue . TfR1 is a transmembrane glycoprotein 
comprised of two identical disulfide bounded sub-
units with a molecular mass of approximately 90 
kDa . Each subunit possesses one binding site for 
the transferrin . Diferric transferrin has a higher af-
finity for TfR1 than monoferric form or iron-free 
apotransferrin . Besides the membrane-associated 
TfR1, a soluble form of this receptor exists in hu-
man serum which represents a soluble fragment 
of the extracellular receptor domain . Soluble 
transferrin receptor (sTfR) is released by proteolyt-
ic cleavage of the protein C-terminal end . It is pro-
posed that release of sTfR is regulated by binding 
of its ligand transferrin (65) . The level of sTfR re-
flects the availability of functional iron .
TfR2 is predominantly expressed in liver, hemato-
poetic cells, duodenal crypt cells, and it overlaps 
with hereditary hemochromatosis protein (HFE) . 
TfR2 binds to HFE and transferrin, but interacting 
domains of HFE with TfR2 are different from those 
of TfR1 . It is assumed that TfR2/HFE complex is re-
Tandara L, Salamunic I . Iron metabolism: current facts 
Biochemia Medica 2012;22(3):311-28 
318
quired for transcriptional regulation of hepcidin 
production by diferric transferrin (66-70) .
Transferrin cycle 
Binding of diferric transferrin to TfR1 at the surface 
of the cell triggers clathrin-mediated endosome 
formation and initiate transferrin cycle . Action of 
proton pump on endosome membrane acidifies 
endosome content and leads to a conformational 
changes of transferrin as well as transferrin recep-
tor, resulting in iron release (71) . Fe(III) is then re-
duced by ferrireductase STEAP3 and iron is trans-
ported across the membrane of endosome into 
the cytoplasm via DMT1 (72) . Apotransferrin is 
then returned to the cell surface completing the 
transferrin cycle and is released to be recharged 
with iron . TfR1 is presented for a new uptake cycle . 
During its lifetime transferrin makes around 100-
200 cycles of iron transport .
After cellular iron uptake iron enters poor charac-
terized “labile iron pool“ (LIP) . LIP is defined as pool 
of iron complexed with low affinity ligands (citrate, 
ATP, amino acids, ascorbic acid or by unidentified 
chaperones) . Recent study identified iron(II)glu-
tathione as the dominant component of this pool 
(73) . LIP represents < 5% of the total cellular iron 
(74) . It is dynamic compartment that supplies iron 
to the mitochondrion for heme and iron sulfur 
cluster synthesis or could be used for synthesis of 
iron-containing proteins in cytosole thereby con-
trolling numerous metabolic reactions . Iron in the 
LIP that exceeds requirement for the synthesis of 
heme and non-heme iron containing proteins is 
stored within ferritin to minimize free iron because 
LIP is catalytically active and capable of initiating 
free radical reactions (75) . Quantification of LIP is 
possible with novel nondisruptive technique that 
use fluorescent metalosensors and may be clini-
cally significant in states of iron overload (76) .
Under normal circumstances entry of transferrin 
bounded iron is the main route of iron entry into 
cells but the pathological accumulation of iron 
leads to transferrin saturation and appearing of 
NTBI which can enter into cells via transferrin-in-
dependent pathway (63) .
Regulation of systemic iron homeostasis
Although iron is very abundant element in environ-
ment its bioavailability is very low so body uses iron 
very rationally . In the same time iron is potentially 
toxic and there is no pathway of regulated excretion 
so absorption in gut must be strictly controlled . 
Those facts dictate the principles of systemic iron 
homeostasis . The bone marrow is the main con-
sumer of circulating iron and the most of the daily 
iron need is used for hemoglobin synthesis in 200 
billion new erythrocytes . In balance, macrophages 
recycle 10–20 times more iron than the intestine ab-
sorbs providing most of daily iron supply . RES mac-
rophages in the spleen and elsewhere phagocytize 
and lyse aged or damaged red blood cells . Heme is 
degraded by HO-1 and iron is liberated from proto-
porphyrin ring and released via ferroportin back to 
plasma transferrin (Figure 2B) (77,78) . Changes in 
iron flux through macrophages affect the mainte-
nance of iron homeostasis more rapidly than chang-
es in iron absorption in enterocytes (79) . Body losses 
1-2 mg of iron per day and about the same amount 
is absorbed in gut in order to provide enough but 
not too much iron to keep stores replete . Therefore, 
systemic iron homeostasis regulates intestinal iron 
absorption, its entry and mobilization from the 
stores in order to meet erythropoietic needs . It also 
assures a stable milieu where each cell regulates 
iron uptake according to its own requirements .
Since its discovery many studies confirmed role of 
liver hormone hepcidin as key regulator of iron ho-
meostasis and placed liver as the central organ of 
system iron homeostasis . This organ synthesizes 
hepcidin, main iron transport protein transferrin 
and stores the most of iron (80,81) .
There is some evidence of kidney involvement in 
iron homeostasis at least when iron demand is 
high . Recently, several iron transport pathways 
have been identified in the kidney but the role of 
kidneys in iron metabolism should be explained 
by future studies (82-84) .
Hepcidin
Hepcidin is negative regulator of iron metabolism . 
On the molecular level it binds to its functional re-
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ceptor ferroportin promoting internalization, and 
finally lysosomal degradation of this iron exporter 
(85) . Loss of ferroportin from cell membrane caus-
es cellular iron retention and represses iron efflux 
from sites of main iron flow (macrophages, hepat-
ocytes and enterocytes) into the blood decreasing 
thus transferrin saturation and reducing iron avail-
ability (Figure 3) (86) .
Dysregulation of hepcidin production, whether 
genetic or acquired, causes iron disorder (Table 2) . 
In healthy individual, an increase of body iron 
would lead to increased hepcidin expression and 
therefore to decreased iron absorption . In pa-
tients affected by HH, because of inadequate or 
ineffective hepcidin-mediated down-regulation 
of ferroportin, iron absorption continues despite 
high body iron load (87,88) . Oppositely, overex-
pression of hepcidin gene is associated with a hy-
poferremic, microcytic, iron refractory anemia 
(89,90) . 
Hepcidin was isolated from human blood in the 
year 2000, during the searching for cysteine rich 
antimicrobial peptides . It is named LEAP-1 (liver 
expressed antimicrobial peptide) (91) . Almost at 
the same time, a peptide was isolated from urine 
and named hepcidin after its hepatic origin and 
antimicrobial effect in vitro (92) . Studies demon-
strated that hepcidin is not liver specific but is also 
expressed in other tissues: the kidney, heart, lungs 
(93) . Hepcidin is synthetized as an 84-amino acid 
(aa) prepropeptide, and is subsequently processed 
into 60–64-aa prohepcidin . Mature and biological-
ly active 25-aa hepcidin is produced by the remov-
al of the proregion with prohormon convertase 
furin (94) . Hepcidin forms simple hairpin structure 


























Figure 3. Maintenance of systemic iron homeostasis by action of hepatic hormone hepcidin .
Liver cells receive multiple signals related to iron balance and respond by transcriptional regulation of iron regulatory hormone 
hepcidin . Hepcidin is negative regulator of iron metabolism that represses iron efflux from sites of main iron flow: macrophages, he-
patocytes and enterocytes decreasing thus transferrin saturation and reducing iron availability . Iron deficiency, hypoxia/anemia and 
increased erythropoietic activity decrease hepcidin expression while iron overload (except HH) and inflammation increase it . 
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lates in plasma as 22-aa peptide and as prohor-
mone pro-hepcidin that lacks biological activity 
(93,96) . Recent study revealed that proregion of 
hepcidin may have bacteriostatic effects, and as 
such may contribute to the innate immune re-
sponse (97) . 
Hepcidin is transcriptionally regulated and there is 
no evidence of other control types . Numerous 
molecules are involved in regulation of its expres-
sion (Table 1) . There are at least four major, sepa-
rate pathways in hepcidin regulation: regulation 
by iron status, dietary iron and iron stores; regula-
tion by inflammation; regulation by hypoxia/ane-
mia; and regulation by erythroid factors (98,99) .
Hepcidin regulation by iron status
Molecular mechanism by which iron stores regu-
late hepcidin synthesis is not completely de-
scribed . HH caused by homozygous disruption of 
HFE, TfR2 and hemojuvelin (HJV) is characterized 
by low level of hepcidin inspite of iron overload in-
dicating that these molecules act as direct or indi-
rect regulators of hepcidin synthesis (100,101) . At 
the subcellular level HJV and TfR2 are localized on 
the same basolateral membrane domain indicat-
ing that interaction of these proteins is possible . 
Localization enables direct contact with blood and 
sensing of signals influenced by iron metabolism 
(102,103) .
HJV gene is identified in the year 2004 and its mu-
tation is identified as a cause of type 2 hereditary 
juvenile hemochromatosis (HJH) (104) . Patients 
with HJH mutations have very low urinary level of 
hepcidin and unlike other form of HH, early age of 
symptoms onset . HJV-mutant mouse exhibit se-
vere iron overload phenotype and complete lack of 
hepcidin expression (101) . HJV is expressed pre-
dominantly in skeletal and cardiac muscle and liver . 
This protein can be expressed as a membrane 
bound and soluble form (sHJV) detected in human 
plasma . It has been proposed that HJV act as co-re-
ceptor that binds to bone morphogenetic protein 
(BMP) ligands and BMP type I and type II receptors 
on the cell surface . This complex (HJV-BMP ligand-
BMP receptors) consequently induces an intracellu-
lar BMP signalling pathway which in turn activates 
the SMAD4 signalling pathway . SMAD complex 
translocate to nucleus and directly increases hepci-
din gene transcription (28,105) . BMP/SMAD signal-
ing cascade of HJV is important for basal regulation 
of hepcidin transcription (106) . Recently, liver trans-
Table 2. Selected iron disorders of genetic origin .
Disease Protein involved Phenotype/inheritance References
HH type 1 HFE Iron overload(autosomal recesive) (153)
HH type 2A Hepcidin Iron overload(autosomal recesive) (154,155)
HH type 2B Hemojuvelin Iron overload(autosomal recesive) (101,104)





Hypotransferrinemia Transferrin Iron overload, anemia(autosomal recesive) (158,159)
Aceruloplasminemia Ceruloplasmin Iron overload, anemia(autosomal recesive) (160)
DMT1-iron overload DMT1 Iron overload, anemia (autosomal recesive) (161)
IRDA Matriptase-2 Iron deficiency anemia(autosomal recesive) (162)
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membrane serine protease, matriptase-2 (type II 
transmembrane serine proteinase; TMPRSS6) 
emerged as an essential component of a pathway 
that detects iron deficiency . It cleaves membrane 
bound HJV increasing sHJV that competitively im-
pairs BMP signaling and blocks transcription of 
hepcidin gene permitting enhanced dietary iron 
absorption (107,108) . Recent study presented data 
that do not confirm cleavage of membrane HJV by 
matriptase-2 in vivo suggesting that its role in hep-
cidin gene regulation could be more complex (109) .
Hepcidin regulation by inflammation
Hepcidin is considered to be the mediator of ACD . 
Hepcidin synthesis is markedly induced by infec-
tion and inflammation . Interleukin 6 (IL-6) is appar-
ently the key inducer of hepcidin synthesis during 
inflammation (110-112) . It regulates hepcidin ex-
pression through signal transducer and activators 
of transcription (STAT3) signaling pathway (113) . 
IL-6 acts on hepatocytes and stimulate hepcidin 
production resulting in cellular iron retention and 
hypoferremia, thus limiting iron availability to 
pathogens (112,114) . Restricted iron availability is 
limiting factor in hemoglobin synthesis and results 
in development of anemia .
Almost all known bacterial pathogens require iron 
to multiply . Iron-withholding strategy is important 
component of innate immunity . Numerous studies 
confirm increased susceptibility to infection in pa-
tients with hemochromatosis due to increased 
iron availability (115) . Decreased serum iron is be-
lieved to contribute to host defense against invad-
ing pathogens and cancer cells (116) . In this sense 
hepcidin emerged as link between immunity and 
iron metabolism and the key mediator of anemia 
of chronic disease (117,118) .
Hepcidin regulation by hypoxia/anemia 
and erythroid factors
When anemia/hypoxia occurs, erythropoietyn ex-
pression increases leading to stimulation of the 
erythropoiesis . In parallel, hepcidin gene expres-
sion decreases, allowing rapid mobilization of iron 
from reticuloendotelial cells and more iron is ab-
sorbed from the duodenal enterocytes to supply 
sufficient iron to erythrocyte precursor cells (119) . 
Several studies indicated that suppression of hep-
cidin is not directly mediated by anemia or but re-
quires tissue hypoxia increased erythropoiesis 
(120,121) . Signals which regulate hepcidin expres-
sion are hierarchically arranged . In diseases char-
acterized by ineffective erythropoesis, like talas-
semias, dominance of the stimulus of erythropoi-
etic demand over the inhibition by iron stores can 
cause iron overload (122) . Studies have shown that 
regulation of hepcidin by erythropoiesis is proba-
bly mediated by bone marrow-derivated signal 
molecules: growth differentiation factor 15 
(GDF15), twisted gastrulation protein homologe 1 
(TWSG1) and hormone erytropoetin (123-125) . 
Suppression of hepcidin in hypoxia is mediated by 
hypoxia inducible factors (HIF) (126,127) .
Regulation of cell iron homeostasis
Since both cellular iron deficiency and iron over-
load are detrimental for cell, iron uptake, storage, 
export and cellular distribution must be tightly 
controlled . Tight regulation of iron assimilation 
prevents an excess of free intracellular element 
that could lead to oxidative stress and damage of 
cellular structures like DNA, proteins and lipid 
membranes by ROS . At the same time it provides 
enough iron in order to meet the metabolic needs . 
Cellular iron uptake and storage are coordinatively 
regulated at the posttranscriptional level by well-
known IRE/IRP system . Cytoplasmic proteins 
known as IRP1 and IRP2 have the ability to ˝sense˝ 
level of iron in transit pool . This proteins bind spe-
cifically to RNA stem-loops known as IRE and post-
transcriptionally modify the expression of proteins 
involved in iron metabolism . 
IREs are stem-loop RNA motifs present on 3´ or 
5´-untranslated mRNA regions (3´-UTR ur 5´-UTR) 
that can interact with IRP . Thus iron itself modu-
lates the synthesis of variety of proteins involved 
in iron metabolism, heme synthesis, tricarboxylic 
acid cycle:
•	 IRE at 5´-UTR mRNA ferritin, ferroportin, cALAS, 
HIF-2-alpha;
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•	 IRE at 3´-UTR mRNA TfR1, DMT1 .
Recently, 35 novel mRNAs that bind IRP1 and IRP2 
were identified as well as cellular mRNAs with ex-
clusive specificity for IRP1 or IRP2 (128) . Spontane-
ous mutations in IRE have been described in hu-
mans . Some genetic defects in L-ferritin IRE result 
in hyperferritinemia-cataract syndrome with 
prominent ocular findings and elevated serum fer-
ritin but with no evidence of disturbed iron home-
ostasis . Mutations in H-ferritin IRE have been ob-
served in cases with familiar iron overload disorder 
(129,130) .
IRP1 is ubiquitously expressed cytosol iron-sulfur 
protein . When cellular iron concentration is suffi-
cient IRP1 acts as an aconitase, cytosol iron-sulfur 
protein, and it lacks RNA binding activity (131) . 
IRP2 functions only as an RNA binding protein 
which is degraded in the presence of iron but in 
the absence of iron it binds to IRE . Alternatively, 
genetic ablation of IRP1 and IRP2 revealed that 
IRP2 dominates iron homeostasis (132) .
IRE-IRP binding has two different effects depend-
ing on the IRE location relative to coding region . 
Binding of IRP to IREs in 3´-UTR region stabilize the 
transcript and prevents mRNA degradation thus 
increasing mRNA translation and protein synthesis 
(Figure 4B) . IRP binding to IREs at 5´-UTRs tran-
script results in translational repression by pre-
cluding ribosome binding and interrupting pro-
tein synthesis (Figure 4A) . 
When cells are iron-sufficient, IRP1/2 lose their af-
finity for RNA binding, consequently ferritin syn-
thesis is activated while TfR1 mRNA is degraded . 
Opposite, when intracellular iron concentration is 
low IRPs bind to IREs of ferritin mRNA at its 5´-UTR 
and block translation, whereas stabilize TfR mRNA 
by binding at 3´-UTR and thus increasing iron up-
take by cell . Iron is neither the only modulator of 
IRP-1 activity nor level of IRP2 . Besides iron, this 
regulatory system is influenced by nitric oxide, 
phosphorilation by protein kinase C, oxidative 
stress and hypoxia/reoxygenation and this pro-
vides a molecular basis by which agents other 
than iron can selectively modulate iron metabo-
lism in cells and tissues (133) .
Future directions 
Although iron metabolism once seemed quite 
simple, discoveries of numerous new molecules 
involved pointed out its complexity . New insights 
on iron metabolism and its regulation at both sys-
tem and cellular level have opened up new diag-
nostic and especially therapeutic options not only 
related to disorders of iron metabolism, but to 
considerably broader spectrum of conditions .
Potential medical applications include develop-
ment of molecules that directly or indirectly mod-
ulate hepcidin expression for the treatment of ac-
quired and hereditary iron overload, or the treat-
ment of ACD (134,135) . Chronic kidney disease 
(CKD) is also associated with increased hepcidin 
levels so hepcidin antagonist could be useful as a 
supplement to erythropoietyn therapy in anemic 
CKD patients, especially in erythropoetin resist-
ance .
Expression of ferroportin and hepcidin seems to 
be important predictors of breast cancer clinical 
outcome . Low ferroportin expression in breast 
cancer tissue provide sufficient amount of meta-
bolically available iron to malignant cells and is in-
dicator of poor breast cancer prognosis (136) . 
Cancer cells have a high iron demands due to 
high metabolic activity so iron deprivation seems 
as an effective method to prevent cancer growth . 
Early clinical studies using iron chelators as anti-
cancer therapy have shown a great promise (137-
139) . Possible modulation in expression of ferro-
portin, mitochondrial ferritin, hepcidin or mole-
cules involved in its regulation could be a target 
of future anticancer drugs . Many studies have 
been recently carried out using transferrin cycle 
for site-specific delivery of therapeutic agents 
into malignant sites that overexpress TfR  . Serum 
transferrin has also a high capacity for binding 
other metal ions of therapeutic or diagnostic in-
terest (140,141) .
Iron chelators have been shown neuroprotective 
and neurorestorative effect in several neurode-
generative diseases such as Parkinson’s and Alz-
heimer’s disease, suggesting that iron chelation 
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might be a promising therapeutic approach for 
those diseases (142,143) .
A natural defence iron-binding protein, lactoferrin 
functions as free iron scavenger in different body 
fluids . Use of recombinant lactoferrin offers new 
therapeutic possibilities for treating bacterial and 
viral infections (144-147) .
In contrast to other markers used for iron status 
detection, changes of serum hepcidin concentra-
tions are frequently direct cause of iron disorders . 
Measurements of serum hepcidin concentrations 
in different clinical settings will help to evaluate 
role of serum hepcidin measurements in diagno-
sis and clinical management of iron disorders 
(148) .
In recent years, number of new molecular partici-
pants in iron metabolism has been characterized . 
Liver hormone hepcidin as a key regulator of iron 
metabolism is discovered . Hepcidin expression in 
liver is regulated by iron status; inflammation; hy-
poxia/anemia and erythroid factors . Hormone acts 
as an iron gatekeeper regulating number of ferro-
portin molecules at cell membrane by binding to 
it and causing its degradation . Loss of ferroportin 
from cell membrane decreases iron release out of 
macrophages, hepatocytes and enterocyes into 
the blood, causing cellular iron retention and de-
creasing iron availability . Disruption of hepcidin 
regulatory circuit is associated with disturbances 
of iron metabolism . Role of newly discovered mol-
ecules involved in regulation of hepcidin expres-
sion like HJV, matriptase-2, GDF-15, TWSG1 needs 
yet to be clarified . New discoveries have answered 
some questions but also have pointed out com-
plexity of iron metabolism . It is certain that com-
pleting the picture of iron metabolism will wait for 
a while .
Potential conflict of interest
None declared .
Figure 4. Maintenance of cellular iron homeostasis by IRE/IRP system . 
In iron deplete cells binding of IRP1/2 at 5´UTR IRE of ferritin and ferroportin mRNA block translation hampering its initiation (A); 
Binding of IRP1/2 at 3´UTR IRE of TfR mRNA stabilize its transcript (B) . In iron replete cells IRP1 act as aconitase and IRP2 is degradated 
by proteases so translation of 5´UTR IRE mRNA of ferritin and ferroportin is carried out undisturbed (C) . In presence of sufficient iron 













































IRP’ act as aconitase
IRP1
IRON DEPLETE CELLS IRON REPLETE CELLS
Tandara L, Salamunic I . Iron metabolism: current facts 
Biochemia Medica 2012;22(3):311-28 
324
1 . Andrews NC . Medical Progress: Disorders of Iron Metabo-
lism . N Engl J Med 1999;341:1986-95 .
2 . WHO . Programme and project: WHO . Available at: http://
www .who .int/nutrition/topics/ida/en/index .html . Acce-
ssed August 10th 2011 .
3 .  Liu K, Kaffes AJ . Iron deficiency anaemia: a review of dia-
gnosis, investigation and managment . Eur J Gastroente-
rol Hepatol 2012;24:109-16 .
4 . Yen AW, Fancher TL, Bowlus CL . Revisiting heredi-
tary hemochromatosis: Current Concepts . Am J Med 
2006;119:391-9 .
5 . Stankowski JN, Dawson VL, Dawson TM . Ironing out 
tau’s role in Parkinsonism . Nat Med 2012;18:291-5 .
6 . Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, 
Wright DK . Tau deficiency induces parkinsonism with de-
mentia by impairing APP-mediated iron export . Nat Med 
2012;18:291-5 .
7 . Huang X, O`Brien PJ, Templeton DM . Mitochondrial in-
volvement in genetically determined transition metal 
toxicity I . Iron toxicity . Chem Biol Interact 2006;163:68-
76 .
8 . Guidi GC, Santonastaso CL . Advancements in ane-
mias related to chronic conditions . Clin Chem Lab Med 
2010;48:1217-26 .
9 . Andrews, NC . Metal transporters and disease . Curr Opin 
Chem Biol 2002;6:181-6 .
10 . Latunde-Dada GO, Simpson JR, Mckie AT . Recent advan-
ces in mammalian haem transport . Trends Biochem Sci 
2006;31:182-8 .
11 . Papanikolaou G, Pantopoulos K . Iron metabolism and 
toxicity . Toxicol Appl Pharmacol 2005;202:199-211 .
12 . Aisen P, Enns C, Wessling-Resnick M . Chemistry and bi-
ology of eucariotic iron metabolism . Int J Biochem Cell 
Biol 2001;33:940-59 . 
13 . Watt RK . Oxido-reduction is not the only mechanism 
allowing ions traverse the ferritin protein shell . Biochim 
Biophys Acta 2010;1800:745-59 .
14 . Puntarulo S . Iron, oxidative stress and human health . 
Mol Aspect Med 2005;26:299-312 .
15 . Kurz T, Gustafsson B, Brunk UT . Cell sensitivity to oxida-
tive stress is influenced by ferritin autophagy . Free Radic 
Biol Med 2011;50:1647–58 .
16 . Chasteen ND, Harrison PM . Mineralization in ferri-
tin: An efficient means of iron storage . J Struct Biol 
1999;126:182-94 .
17 . De Domenico I, Ward DM, Kaplan J . Specific iron che-
lators determine route of ferritin degradation . Blood 
2009;114:4546-51 .
18 . Asano T, Komatsu M, Iwai YY, Ishikawa F, Mizushima N, 
Iwai K . Distinct mechanisms of ferritin delivery to lysoso-
mes in iron-depleted and iron-replete cells . Mol Cell Biol 
2011;31:2040-52 .
19 . Surguladze N, Thompson KM, Beard JL, Connor JR, Fried 
MG . Interaction and reactions of ferritin with DNA . J Biol 
Chem 2004;279:14694-702 .
20 . Alkhateeb A, Connor JR . Nuclear ferritin: A new role 
for ferritin in cell biology . Biochim Biophys Acta 
2010;1800:793-7 .
21 . Bou-Abdallah F, Santambrogio P, Levi S, Arosio P, Chaste-
en ND . Unique iron binding and oxidation properties of 
human ferritin: A comparative analysis with human H-
chain ferritin . J Mol Biol 2005;347:543-54 .
22 . Nie GN, Chen G, Sheftel AD, Pantopoulos K, Ponka P . In 
vivo tumor growth is inhibited by cytosolic iron depriva-
tion caused by the expression of mitochondrial ferritin . 
Blood 2006;108:2428-34 .
23 . Richardson DR, Lane HJR, Becker E, Huang MLH, Whit-
nhall M, Rahmanto YS, et al . Mitochondrial iron traffic-
king and the integration of iron metabolism between 
the mitochondrion and cytosol . Proc Natl Acad Sci U S A 
2010;107:10775-82 .
24 . Santambrogio P . Over-expression of mitochondrial ferri-
tin affects the JAK2/STAT5 pathway in K562 cells and 
cause mitochondrial iron accumulation . Haematologica 
2011;96:1424–32 .
25 . Choen LA . Serum ferritin is derivied primarly from ma-
crophages through a nonclassical secretory pathway . 
Blood 2010;116:1574-84 .
26 . Wang W . Serum ferritin: Past, present and future . Bioc-
him Biophys Acta 2010;1800:760-9 .
27 . De Domenico I, Vaughn MB, Paradkar PN, Lo E, Ward DM, 
Kaplan J . Decoupling ferritin synthesis from free cytosolic 
iron results in ferritin secretion . Cell Metab 2011;13:57–
67 .
28 . Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, et al . A role 
of SMAD4 in iron metabolism through the positive re-
gulation of hepcidin expression . Cell Metab 2005;2:399-
409 .
29 . Fisher J, Devraj K, Ingram J, Slagle-Webb B, Madhanku-
mar AB, X Liu, et al . Ferritin: A novel mechanism for de-
livery of iron to the brain and other organs . Am J Physiol 
Cell Physiol 2007;293C641-9 .
30 . Han J, Seaman WE, Di X, Wang W, Willingham M, Torti 
FM, et al . Iron uptake mediated by binding of H-ferritin 
to the TIM-2 receptor in mouse cells . PLoS ONE 6: e23800 . 
31 . Cavill I . Iron and erythropoietin in renal disease . Nephrol 
Dial Transplant 2002;17:19-23 .
32 . Finch C . Regulators of iron balance in humans . Blood 
1994;6:1697-702 .
33 . Ozaki M, Awai T, Kawabata M . Iron release from haemo-
siderin and production of iron-catalysed hidroxyl radi-
cals in vitro . Biochem J 1988;250:589-95 .
34 . Umbreit J . Iron deficiency: A Concise Review . Am J Hema-
tol 2005;78:225-31 .
35 . Munoz M, Garcia-Erce JA, Remacha AF . Disorders of iron 
metabolism . Part 1: molecular basis of iron homeostasis . 
J Clin Pathol 2011;64:281-6 .
36 . Conrad ME, Umbreit JN . Pathways of iron absorption . 
Blood Cells Mol Dis 2002;29:336-55 .
37 . McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, San-
ger G, Mudaly E, et al . An iron-regulated ferric reducta-
References
Tandara L, Salamunic I . Iron metabolism: current facts 
Biochemia Medica 2012;22(3):311-28 
  325
se associated with the absorption of dietary iron . Scien-
ce 2001;291:1755-9 .
38 . Atanasova B, AC Li, Bjarnason I, Tzatchev KN, Simpson 
RJ . Duodenal ascorbate and ferric reductase in human 
iron deficiency . Am J Clin Nutr 2005;81:130-3 .
39 . Ohgami RS, Campagna DR, McDonald A, D Fleming . 
The Steap proteins are matalloreductases . Blood 
2006;108:1338-94 .
40 . Canonne-Hergaux F, Gruenhied S, Ponka P, Gross P . Cellu-
lar and subcellular localisation of the Nramp2 iron tran-
sporter in the intestinal brush border and regulation by 
dietary iron . Blood 1999;93:4406-17 .
41 . Garric MD, Singleton ST, Vargas F, Kuo HC, Zhao L, 
Knopfrl M . DMT1: Which metals does it transport? Biol 
Res 2006;39:79-85 .
42 . Conrad ME, Umbreit EG, Moore LN, Porubcin M, Ha-
insworth MJ, Simovich MT, et al . Separate pathways for 
cellular uptake of ferric and ferrous iron . Am J Physiol Ga-
strointest Liver Physiol 2000;279:767-74 .
43 . Umbreit JN, Conrad, ME, Hainsworth LN, Simovich M . 
The ferrireductase paraferritin contains divalent metal 
transporter as well as mobilferrin . Am J Physiol Gastroin-
test Liver Physiol 2002;282:534-39 .
44 . Ranganathan PN, Lu Y, Fuqua BK, Collins JF . Immunore-
active hephaestin and ferroxidase activity are present in 
the cytosolic fraction of rat enterocytes . Biometals 2012 
[Epub ahead of print] . 
45 . Simovich MJ, Conrad ME, Umbreit JN, Moore EG, Ha-
insworth LN, Smith HK . Cellular localisation of proteins 
related to iron absorption and transport . Am J Hematol 
2002;69:164-70 .
46 . Hou S, Reynolds MF, Horrigan FT, Heinemann SH, Hoshi T . 
Reversible binding of heme to proteins in cellular signal 
transduction . Acc Chem Ress 2006;39:918-24 .
47 . Latunde-Dada GO, Takeuchi K, Simpson RJ, McKie AT . 
Haem carrier protein 1 (HCP1): Expression and functi-
onal studies in cultured cells . FEBS Lett 2006;580:6865-
870 .
48 . Shayeghi, M, Latunde-Dada GO, Oakhill JS, Laftah AH, 
Takeuchi K, Halliday N . Identification of an intestinal 
heme transporter . Cell 2005;122:789–801 .
49 . Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, 
Tsai E, et al . Identiﬁcation of an intestinal folate tran-
sporter and the molecular basis for hereditary folate ma-
labsorption . Cell, 2006;127:917–28 .
50 . Gantz T, Nemeth E . Regulation of iron aquisition and 
iron distribution in mamals . Biochim Biophys Acta 
2006;1763:690-9 . 
51 . Ma Y, Yeh M, Yeh K, Glass J . Iron Imports V: Transport of 
iron through the intestinal epithelium . Am J Physiol Ga-
strointest Liver Physiol 2006;290:417-22 .
52 .  Philpott CC . Coming into view: eukaryotic iron chape-
rones and intracellular iron delivery . J Biol Chem 
2012;287:13518-23 .
53 . Shi H, Bencze KZ, Stemmler TL, Philpott CC . A cytoso-
lic iron chaperone that delivers iron to ferritin . Science 
2008;320:1207–10 .
54 . McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K . A no-
vel duodenal iron-regulated transporter, IREG1, implica-
ted in the basolateral transfer of iron to the circulation . 
Mol Cell 2000;5:299-309 .
55 . McKie AT, Barlow DJ . The SLC40 basolateral iron tran-
sporter family (IREG1/ferroportin/MTP1) . Pflugers Arch 
2004;447:801-6 .
56 . Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libi-
na N, et al . Hephaestin, a ceruloplasmin homologue im-
plicated in intestinal iron transport, is defective in the 
SLA mouse . Nat Genet 1999;21:195-9 .
57 . Harris ZL, Durley AP, Man TK, Gitlin JD . Targeted gene dis-
ruption reveals an essential role for ceruloplasmin in cel-
lular iron efflux . Proc Natl Acad Sci U S A 1999:96:10812-
17 .
58 . Canonne-Hergaux F, Donovan A, Delaby C, Wang H, Gro-
ss P . Comparative studies of duodenal and macropha-
ge ferroportin proteins . Am J Physiol Gastrointest Liver 
Physiol 2006;290:156-63 .
59 . Zhang LI, Senecal T, Ghosh MC, Ollivierre-Wilson H, Tu T, 
Roault TA . Hepcidin regulates ferroportin expression and 
intracellular iron homeostasis of erythroblasts Blood, 
2011;118:2868-77 .
60 . Gkouvatsos K, Papanikolaou G, Pantopoulos K . Regula-
tion of iron transport and the role of transferrin . Biochim 
Byophys Acta 2012;1820:188-202 .
61 . Baker HM, Anderson BF, Baker EN . Dealing with iron: 
Common structural principles in proteins that transport 
iron and heme . Proc Natl Acad Sci U S A 2003;100:3579-
83 .
62 . Duk-Hee L, David R, Jacobs JR . Serum markers of sto-
red body iron are not appropriate markers of health 
effect of iron: a focus on serum ferritin . Med Hypotheses 
2004;62:442-5 .
63 . Brissot P, Ropert M, Lan CL, Loreal O . Non-transferrin bo-
und iron: A key role in iron overload and iron toxicity . Bio-
chim Biophys Acta 2012;1820:403-10 .
64 . Aisen P . Transferin receptor 1 . Int J Biochem Cell Biol 
2004;36: 2137-43 .
65 . Dassler K, Zydek M, Wandzik K, Kaup M, Fuchs H . Rele-
ase of the soluble transferrin receptor is directly regula-
ted by binding of its ligand ferritransferrin . J Biol Chem 
2006;6:3297-304 .
66 . Gao J, Kramer J, Chen M, Tsukamoto H, Enns AS, Zhang 
CA . Interaction of the hereditary hemochromato-
sis protein HFE with transferin receptor 2 is required for 
transferrin-induced hepcidin expression . Cell Metab 
2009;9:217-27 .
67 . Rapisarda C, Puppi J, Hughes RD, Dhawan A, Fernaud S, 
Evans RW, et al . Transferrin receptor 2 is crucial for iron 
sensing in human hepatocytes . Am J Physiol Gastroin-
test Liver Physiol 2010;299:G778-83 .
68 . Falzacappa MVV, Muckenthaler MU . Hepcidin: hormone 
and anti-microbial peptide . Gene 2005;364:37-44 .
69 . Goswami T, Andrews CN . Hereditary hemochromato-
sis protein, HFE: interaction with transferin receptor 1 
suggests a molecular mechanism of iron sensing . J Biol 
Chem 2006;281:28494-8 .
Tandara L, Salamunic I . Iron metabolism: current facts 
Biochemia Medica 2012;22(3):311-28 
326
70 . Wallace D, Summervile L, Subramaniam VN . Targeted 
disruption of hepatic transferrin receptor 2 gene in mice 
leads to iron overload . Gastroenterology 2007;132:301-
10 .
71 . Ponka P, Lok CN . The transferrin receptor: role in health 
and disease . Biochem Cell Biol 1999;31:1111-37 .
72 . Ohgami RS, Campagna DR, Greer EL, McDonald B, Chen 
A, Antiochos J, et al . Identification of ferrireductase requ-
ired for efficient transferrin-dependent iron uptake in 
erithroyd cells . Nat Genet 2005;37:1264-9 .
73 . Hider RC, Kong XL . Glutathione: a key component of the 
cytoplasmic labile iron pool . Biometals 2011;24:1179-87 .
74 . Andrews NC . Probing the iron pool . Focus on “Detection 
of intracellular iron by its regulatory effect” . Am J Physiol 
Cell Physiol 2004;287:C1537-8 .
75 . Schneider BD, Leibold EA . Regulation of mammali-
an iron homeostasis . Curr Opin Clin Nutr Metab Care 
2000;3:267-73 .
76 . Kakhlon O, Cabantchik ZI . The labile iron pool: characte-
rization, and participation in cellular processes . Free Ra-
dic Biol Med 2002;8:1037-46 .
77 . Knutson MD, Oukka M, Koss LM, Aydemi F, Wessling-
Resnick M . Iron release from macrophages after eryt-
hrophagocytosis is up-regulated by ferroportin1 ove-
rexpression and down-regulated by hepcidin . Proc Natl 
Acad Sci U S A 2005;102:1324-8 .
78 . Poss KD, Tonegawa S . Heme oxygenase 1 is required for 
mammalian iron reutilization . Proc Natl Acad Sci U S A 
1997;94:10919-24 .
79 . Roy C, Andrews NC . Anemia of inflammation: the hepci-
din link . Curr Opin Hematol 2005;12:107-11 .
80 . Detivaud L, Nemeth E, Boudjema K, Turlih B, Troadec MB, 
Leroyer P, et al . Hepcidin levels in humans are correlated 
with hepatic iron stores, hemoglobin levels and hepatic 
function . Blood 2005;106:746-8 .
81 . Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf 
JI, Andrews C . Inappropriate expression of hepcidin is 
associated with iron refractory anemia: implication for 
anemia of chronic disease . Blood 2002;100:3776-81 .
82 . Veuthey T, D´Anna MC, Roque ME . Role of the kidney in 
iron homeostasis: renal expresion of prohepcidin, ferro-
portin, and DMT1 in anemic mice . Am J Physiol Renal 
Physiol 2008;295:F1213-21 .
83 . Kulaksiz, H Theiling F, Bachman S, Gherke SG, Rost D, Ce-
tini A, Janetzko Y, et al . The iron regulatory protein hepci-
din: expression and cellular localization in the mammali-
an kidney . J Endocrinol 2005;184:361-70 .
84 . Smith CP, Thevenod F . Iron transport and the kidney . Bio-
chim Biophys Acta 2009;1790:724-30 .
85 . De Domenico I, Ward DM, Langelier C, Vaughn MB, Ne-
meth E, Sundquist WI, et al . The molecular mechanism 
of hepcidin-mediated ferroportin down-regulation . Mol 
Biol Cell 2007;18:2569-78 .
86 . Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan 
A, Ward DM . Hepcidin regulates cellular iron efflux by 
binding to ferroportin and inducing its internalization . 
Science 2004;306:2090-93 .
87 . Sangwaiya A, Manglam V, Busbridge M, Thursz M, Arno-
ld J . Blunted increase in serum hepcidin as response to 
oral iron in HFE-hemochromatosis . Eur J Gastroenterol 
Hepatol 2011;23:721-4 .
88 . Anderson GJ, Frazer DM, McKie AT, Vulpe CD, Smith A . 
Mechanisms of haem and non-haem iron absorption: 
Lessons from inherited disorders of iron metabolism . Bi-
ometals 2006;18:339-48 .
89 . Chung AYF, Leo KW, Wong GC, Chuah KL, Ren JW, Lee 
CGL . Giant hepatocelullar adenoma presenting with 
chronic iron deficiency anemia . Am J Gastroenterol 
2006;101:2160-2 .
90 . Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, 
Grandchamp B, et al . Severe iron deficiency anemia in 
transgenic mice expressing liver hepcidin . Proc Natl Acad 
Sci U S A 2002;99:4596-601 .
91 . Krause A, Neitz S, Magert HJ, Shulz A, Forssmann WG, 
Anderman P, Shulz-Knappe K . LEAP-1, a novel higly disul-
fide-bounded human peptide, exhibits antimicrobial ac-
tivity . FEBS Lett 2000;750:147-50 .
92 . Park CH, Valore EV, Waring AJ, Ganz T . Hepcidin, a uri-
nary antimicrobial peptide syntetized in liver . J Biol 
Chem 2001;276:7806-10 .
93 . Kulaksiz H, Gherke DG, Rost A, Janetzko D, Kallinowski 
T, Bruckner B, Stremmel W . Pro-hepcidin: expression and 
cell specific localisation in the liver and its regulation in 
hereditary haemochromatosis, chronic renall insuffici-
ency, and renal anemia . Gut 2004;53:735-43 .
94 . Valore E, Ganz T . Posttranslational processing of hep-
cidin in human hepatocytes is mediated by the prohor-
mon convertase furin . Blood Cells Mol Dis 2008;40:132-
38 .
95 . Hunter HN, Fulton DB, Ganz T, Vogel HJ . The soluti-
on structure of human hepcidin, a peptide hormone 
with antimicrobial activity that is involved in iron up-
take and hereditary hemochromatosis . J Biol Chem 
2002;277:37597-603 .
96 . Gagliardo B, Kubat N, Faye A, Jaouen M, Durel B, Des-
chemin JC, et al . Pro-hepcidin is unable to degrade iron 
exporter ferroportin unless maturated by furin-depen-
dent process . J Hepatol 2009;50:394-401 .
97 . Barthe C, Hocquellet A, Garbay B . Bacteriostatic activity 
of the proregion of human hepcidin . Protein Pept Lett 
2011;18:36-40 .
98 . Zhang AS, Enns CA . Molecular mechanisms of normal 
iron homeostasis . Hematology Am Soc Hematol Educ 
Program 2009:207-14 .
99 . Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma 
H, Swinkels DW . Regulation of hepcidin: insights from bi-
ochemical analyses on human serum samples . Blood 
Cells Mol Dis 2008;40:339-46 .
100 . Drake SF, Herbison EH, Morgan CE, Delima R, Graham 
RM, Chua ACG, et al . Iron absorption and hepatic iron 
uptake are increased in transferrin receptor 2 (Y245X) 
mutant mouse model of hemochromatosis type 3 . Am J 
Physiol Gastrointest Liver Physiol 2006;292:G323-8 .
Tandara L, Salamunic I . Iron metabolism: current facts 
Biochemia Medica 2012;22(3):311-28 
  327
101 . Niederkofler V, Salie R, Arber S . Hemojuvelin is essentioal 
for dietary iron sensing, and its mutation leads to severe 
iron overload . J Clin Invest 2005;115:2180-6 .
102 . Merle U, Theiling F, Fein E, Gherke S, Riedel B, Kalli-
nowski HD, et al . Localization of the iron-regulatory pro-
teins hemojuvelin and transferrin receptor 2 to the ba-
solateral domain of hepatochytes . Histochem Cell Biol 
2007;127:221-6 .
103 . Chen J, Enns C . Hereditary hemochromatosis and tran-
sferrin receptor 2 . Biochim Biophys Acta 2012;1820:256-63 .
104 . Papanikolaou G, Samuels ME, Ludwig EH, MacDonald 
MLE, Franchini PL, Dube MP, et al . Mutations in HFE2 
cause iron overload in chromosome 1q-linked juvenile 
hemochromatosis . Nat Genet 2004;36:77-82 .
105 . Babitt JL, Huang WH, Wrighting DM, Xia Y, Sidis Y, Sa-
mad TA, et al . Bone morphogenetic protein signaling by 
hemojuvelin regulates hepcidin expression . Nat Genet 
2006;38:531-39 .
106 . Bartnikas TB, Fleming MD . Hemojuvelin is essential for 
transferrin-dependent and transferrin-independent hep-
cidin expression in mice . Haematologica 2012;97:189-92 .
107 . Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, et al . The seri-
ne protease TMPRSS6 Is required to sense iron deficiency . 
Science 2008;320:1088-92 .
108 . Finberg KE, Whittlesey RL, Fleming MD, Andrews NC . 
Down-regulation of Bmp/Smad signaling by Tmprss6 is 
required for maintanance of systemic iron homeostasis . 
Blood 2010;115:3817-26 .
109 . Krijt J, Fujikura Y, Ramsay AJ, Velasco G, Nečas E . Liver he-
mojuvelin protein levels in mice deficient in matriptase-2 
(Tmprss6) . Blood Cells Mol Dis 2011;47:133-7 .
110 . Lee P, Peng H, Gelbart T, Beutler E . The IL-6 and lipo-
polysaccharide-induced transcription of hepcidin in HFE, 
transferrin receptor 2 and beta-2-microglobulin-defici-
ent hepatocytes . Proc Natl Acad Sci U S A 2004;101:9263-
5 .
111 . Nemeth E, Valore EV, Territo M, Schiller G, Lichenste-
in A, Ganz T . Hepcidin, putative mediator of anemia 
of inflammation, is type II acute-phase protein . Blood 
2003;101:2461-3 .
112 . Kemna EP, Nemeth E, van der Hoeven H, Pickkers, Swin-
kels D . Time course analysis of hepcidin, serum iron, and 
plasma cytokine levels in humans injected with LPS . Blo-
od 2005;106:1864-6 .
113 . Wrighting D, Andrews NC . Interleukin-6 induces hepcidin 
expression through STAT3 . Blood 2006;108:3204-9 .
114 . Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Peder-
sen BK, et al . IL-6 mediates hypoferremia of inflammati-
on by inducing the synthesis of the iron regulatory hor-
mone hepcidin . J Clin Invest 2004;113:1271-6 .
115 . Khan FA, Fisher MA, Khakoo RA . Association of he-
mochromatosis with infectious diseases: expanding 
spectrum . Int J Infect Dis 2007;11:482-7 .
116 . Ong ST, Ho JZ, Ho B, Ding JL . Iron-withholding strategy 
in innate immunity . Immunobiology . 2006;211:295-314 .
117 . Theur I, Schroll A, Nairz M, Selfert M, Theurl M, Sonnwe-
ber T, et al . Pathways for the iron regulation of hepcidin 
expression in anemia of chronic disease and iron defici-
ency anemia in vivo . Haematologica 2011;96:1761-9 .
118 . Vyoral D, Petrak J . Hepcidin: A direct link between iron 
metabolism and immunity Int J Biochem Cell Biol 
2005;37:1768-73 .
119 . Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, De-
vaux I, et al . The gene encoding iron regulatory peptide 
hepcidin is regulated by anemia, hypoxia and inflamma-
tion . J Clin Invest 2002;110:1037-44 .
120 . Pak M, Gabayan MA, Lopez V, Ganz T, Rivera S . Suppressi-
on of hepcidin during anemia requires erythropoietic ac-
tivity . Blood 2006;12:3730-5 .
121 . Vokurka M, Krijt J, Sulc K, Necas E . Hepcidin mRNA levels 
in mouse liver respond to inhibition of erythropoiesis . 
Physiol Res 2006;55:667-74 .
122 . Kattamis A, Papassotiriou I, Palaiogou D, Galani F, Apo-
stolakou A, Ladis V, et al . The effect of erythropoetic ac-
tivity and iron burden on hepcidin expression in patients 
with thalassemia major . Haematologica 2006;91:809-
12 .
123 . Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Car-
valho F, et al . Erythropoietin mediates hepcidin expressi-
on in hepatocytes through EPOR signaling and regulati-
on of C/EBPalpha . Blood 2008;111:5727–33 .
124 . Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et 
al . High levels of GDF15 in thalassemia suppress expre-
ssion of the iron regulatory protein hepcidin . Nat Med 
2007;13:1096–101 .
125 . Tanno T, Porayette A, Orapan S, Noh SJ, Byrnes C, Bhupa-
tiraju A, et al . Identification of TWSG1 as a second novel 
erythroid regulator of hepcidin expression in murine and 
human cells . Blood 2009;114:181–6 .
126 . Lakhal S, Schödel J, Townsend ARM, Pugh CW, Ratcliffe 
PJ, Mole DR, et al . Regulation of type II transmembrane 
serine proteinase TMPRSS6 by hypoxia-inducible factors . 
J Biol Chem 2011;286:4090-7 .
127 . Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Ran-
kin E, Vaulont S, Haase VH, et al . Regulation of iron ho-
meostasis by the hypoxia-inducible transcription factors 
(HIFs) . J Clin Invest 2007;117:1926–32 .
128 . Sanchez M, Galy B, Schwanhaeusser B, Blake J, Bähr-Iva-
cevic T, Benes V, et al . Iron regulatory protein-1 and -2: 
transcriptome-wide definition of binding mRNAs and 
shaping of the cellular proteome by iron regulatory pro-
teins . Blood 2011;118:168-79 .
129 . Beaumont C, Leneuve P, Devaux I, Scoazec JY, Ber-
thier M, Loiseau MN, et al . Mutation in the iron respon-
sive element of the L ferritin mRNA in a family with do-
minant hyperferritinaemia and cataract . Nat Genet 
1995;11:444-6 .
130 . Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takaya-
ma T, et al . A mutation, in the iron-responsive element of 
H ferritin mRNA, causing autosomal dominant iron over-
load . Am J Hum Genet 2001;69:191-7 .
131 . Clarke SL, Vasanthakumar A, Anderson SA, Pondarre C, 
Koh CM, Deck KM, et al . Iron-responsive degradation of 
regulatory protein 1 does not require the Fe-S cluster . 
EMBO J 2006;25:544-53 .
Tandara L, Salamunic I . Iron metabolism: current facts 
Biochemia Medica 2012;22(3):311-28 
328
132 . Meyron-Holtz EG, Gosh MC, LaVaute I, Brazzolotto T, Ka-
zuhiro X, Berger UV, et al . Genetic ablations of iron regu-
latory proteins 1 and 2 reveal why iron regulatory protein 
2 dominates iron homeostasis . EMBO J 2004;23:386-95 .
133 . Eisenstein RS, Biemings KP . Iron regulatory proteins, 
iron responsive elements and iron homeostasis . J Nutr 
1998;128:2295-98 .
134 . Sasu BJ, Cooke KS, Arvedson TI, Plewa C, Ellison AR, 
Sheng J, et al . Antihepcidin antibody treatment modu-
lates iron metabolism and is effective in a mouse model 
of inflammation-induced anemia . Blood 2010;115:3616-
24 .
135 . Gantz T . Hepcidin in iron metabolism . Curr Opin Hema-
tol 2004;11:251-4 .
136 . Pinnix ZK, Miller LD, Wang W, D`Agostino R, Kute T, Willi-
ongham MC, et al . Ferroportin and iron regulation in 
breast cancer progression and prognosis . Sci Transl Med 
2010;43:43-5 .
137 . Chaston TB, Wats RN, Yuan J, Richardson DR . Potent an-
titumor activity of novel iron chelators derivied from di-
2-pyridylketone isonicotinyl hydrazone involves fen-
ton-derived free radical generation . Clin Cancer Res 
2004;10:7365-74 .
138 . Chantrel-Groussard K, Gaboriau F, Pasdeloup N, Havou-
is R, Nick H, Pierre JL, et al . A new orally active iron che-
lator ICL670A exhibits a higher antiproliferative effect in 
human hepatocyte cultures than O-trensox . Eur J Phar-
macol 2006;541:129-37 .
139 . Whitnall M, Howard J, Ponka P, Ritchardson DR . A class 
of iron chelators with a wide spectrum of potent antitu-
mor activity that overcomes resistance to chemothera-
peutics . Proc Natl Acad Sci U S A 2006;103:14901-6 .
140 . Quian ZM, Li H, Sun H, Ho K . Targeted drug delivery via 
the transferrin-receptor mediated endocytosis pathway . 
Pharmacol Rev 2002;54:561-84 .
141 . Li H, Sun H, Quian ZM . The role of the transferrin-tran-
sferrin receptor- system in drug delivery and targeting . 
Trends Pharmacol Sci 2002;23:206-9 .
142 .  Li X, Jankovic L, Lee W . Iron chelation and neuropro-
tection in neurodegenerative diseases . J Neural Transm 
2011;118:373-7 .
143 . Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin 
M, Youdim MBH . Therapeutic targets and potential of 
the novel brain-permeable multifunctional iron che-
lator-monoamine oxidase inhibitor drug, M-30, for 
the treatment of Alzheimer´s disease . J Neurochem 
2007;100:490-502 .
144 . Kelly R, Giaccone G . The role of talactoferrin alfa in the 
treatment of non-small cell lung cancer . Expert Opin Biol 
Ther 2010;10:1379-86 .
145 . Weinberg, ED . Human lactoferrin: a novel therapeu-
tic with broad spectrum potential . J Pharm Pharmacol 
2001;53:1303-10 .
146 . Weinberg, ED . Iron withholding: a defense against viral 
infections . Biometals 1996;9:393-9 .
147 . Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Po-
limeni A, et al . Antiviral properties of lactoferrin: A natu-
ral immunity molecule . Molecules 2011;16:6992-7018 .
148 . Ganz T, Olbina G, Girelli D, Nemeth E, Westerman 
M . Immunoassay for human serum hepcidin . Blood 
2008;112:4292-7 .
149 . White KN, Conesa C, Sánchez L, Amini M, Farnaud S, 
Lorvoralak C, et al . The transfer of iron between ce-
ruloplasmin and transferrins . Biochim Biophys Acta 
2012;1820:411-6 . 
150 . Ward PP, Conneely OM . Lactoferrin: role in iron homeo-
stasis and host defense against microbial infection . Bio-
metals 2004:17:203-8 .
151 . Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A et al . 
Iron traffics in circulation bound to a siderocalin (Ngal)-
catechol complex . Nat Chem Biol 2010;6:602-9 . 
152 . Pandolfo M, Pastore A . The pathogenesis of Friedreich 
ataxia and the structure and function of frataxin . J Neu-
rol 2009;256(Suppl . 1):9-17 .
153 . FederJN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, 
Basava A, et al . A novel MHC class I-like gene is mutated 
in patients with hereditary haemochromatosis . Nat Ge-
net 1996;13:399-408 .
154 . Hattori A, Tomosugi N, Tatsumi Y, Suzuki A, Hayashi K, 
Katano Y, et al . Identification of a novel mutation in the 
HAMP gene that causes non-detectable hepcidin mole-
cules in a Japanese male patient with juvenile hemoc-
hromatosis . Blood Cells Mol Dis 2012;48:179-82 .
155 . Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, 
Christakis J, et al . Mutant antimicrobial peptide hepcidin 
is associated with severe juvenile hemochromatosis Na-
ture Genetics 2002;33:21-2 .
156 . Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen 
JW, Breuning MH, et al . A mutation in SLC11A3 is asso-
ciated with autosomal dominant hemochromatosis . Nat 
Genet 2001;28:213-4 .
157 . Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Ca-
ssanelli S, et al . Autosomal-dominant hemochromato-
sis is associated with a mutation in the ferroportin (SL-
C11A3) gene . J Clin Invest 2001;108:619-23 .
158 . Hamill RL, Woods JC, Cook BA . Congenital atransferrine-
mia . A case report and review of the literature . Am J Clin 
Pathol 1991;96:215-8 . 
159 . Shamsian BS, Rezaei N, Arzanian MT, Alavi S, Khojasteh 
O, Eghbali A . Severe hypochromic microcytic anemia in a 
patient with congenital atransferrinemia . Pediatr Hema-
tol Oncol 2009;26:356-62 .
160 . Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto 
K, Morita H et al . A mutation in the ceruloplasmin gene is 
associated with systemic hemosiderosis in humans Na-
ture Genetics 1995;9:267-72 .
161 . Mims MP, Guan Y, Pospisilova D, Priwitzerova M, Indrak 
K, Ponka P, et al . Identification of a human mutation of 
DMT1 in a patient with microcytic anemia and iron over-
load . Blood 2005;105:1337-42
162 . De Falco L, Totaro F, Nai A, Pagani A, Girelli D, Silvestri 
L, et al . Novel TMPRSS6 mutations associated with iron-
refractory iron deficiency anemia (IRIDA) . Hum Mutat . 
2010;31:E1390-405 .
